JW Asset Management LLC Sells 21,091 Shares of Establishment Labs Holdings Inc. $ESTA

JW Asset Management LLC lowered its stake in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 0.7% during the 4th quarter, Holdings Channel.com reports. The firm owned 3,061,694 shares of the company’s stock after selling 21,091 shares during the quarter. Establishment Labs accounts for approximately 72.6% of JW Asset Management LLC’s portfolio, making the stock its biggest position. JW Asset Management LLC owned 0.11% of Establishment Labs worth $223,136,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in ESTA. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Establishment Labs by 20.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 57,215 shares of the company’s stock valued at $2,335,000 after purchasing an additional 9,557 shares during the period. Geode Capital Management LLC raised its holdings in shares of Establishment Labs by 1.2% during the second quarter. Geode Capital Management LLC now owns 25,917 shares of the company’s stock valued at $1,105,000 after purchasing an additional 299 shares during the period. WINTON GROUP Ltd acquired a new position in shares of Establishment Labs during the second quarter valued at about $651,000. Nebula Research & Development LLC raised its holdings in shares of Establishment Labs by 27.9% during the second quarter. Nebula Research & Development LLC now owns 16,214 shares of the company’s stock valued at $692,000 after purchasing an additional 3,538 shares during the period. Finally, Sei Investments Co. raised its holdings in shares of Establishment Labs by 13.3% during the second quarter. Sei Investments Co. now owns 48,428 shares of the company’s stock valued at $2,068,000 after purchasing an additional 5,668 shares during the period. Institutional investors and hedge funds own 72.91% of the company’s stock.

Establishment Labs Trading Up 1.7%

ESTA opened at $71.23 on Friday. The company has a debt-to-equity ratio of 16.82, a current ratio of 2.96 and a quick ratio of 1.91. Establishment Labs Holdings Inc. has a fifty-two week low of $33.35 and a fifty-two week high of $83.31. The firm has a market capitalization of $2.10 billion, a PE ratio of -47.81 and a beta of 1.12. The company’s 50-day moving average is $64.47 and its 200 day moving average is $67.91.

Establishment Labs (NASDAQ:ESTA) last posted its earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.10). The business had revenue of $59.88 million during the quarter, compared to analyst estimates of $57.40 million. Establishment Labs had a negative return on equity of 218.77% and a negative net margin of 19.05%.The company’s revenue was up 44.7% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.70) EPS. As a group, research analysts predict that Establishment Labs Holdings Inc. will post -1.07 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on ESTA shares. Canaccord Genuity Group upped their target price on shares of Establishment Labs from $85.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, February 26th. Weiss Ratings restated a “sell (e+)” rating on shares of Establishment Labs in a report on Friday, March 27th. Stephens upped their target price on shares of Establishment Labs from $85.00 to $90.00 and gave the stock an “overweight” rating in a report on Wednesday, February 25th. BTIG Research upped their target price on shares of Establishment Labs from $88.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Finally, Citigroup restated a “neutral” rating on shares of Establishment Labs in a report on Wednesday, May 6th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $87.14.

Insider Buying and Selling

In other Establishment Labs news, Director Quiros Juan Jose Chacon sold 105,000 shares of the stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $75.42, for a total value of $7,919,100.00. Following the completion of the sale, the director owned 927,504 shares in the company, valued at approximately $69,952,351.68. This trade represents a 10.17% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In the last ninety days, insiders have sold 330,000 shares of company stock valued at $22,854,538. Company insiders own 9.99% of the company’s stock.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.